Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
NVGN's Cash-to-Debt is ranked higher than
98% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. NVGN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NVGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.92  Med: 2235.53 Max: No Debt
Current: No Debt
Equity-to-Asset 0.71
NVGN's Equity-to-Asset is ranked higher than
60% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NVGN: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
NVGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.79 Max: 0.97
Current: 0.71
0.32
0.97
Piotroski F-Score: 1
Altman Z-Score: -6.14
Beneish M-Score: 3.36
WACC vs ROIC
9.72%
-123.89%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -4113.25
NVGN's Operating Margin % is ranked lower than
97% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. NVGN: -4113.25 )
Ranked among companies with meaningful Operating Margin % only.
NVGN' s Operating Margin % Range Over the Past 10 Years
Min: -9158.43  Med: -579.76 Max: -165.72
Current: -4113.25
-9158.43
-165.72
Net Margin % -4285.14
NVGN's Net Margin % is ranked lower than
96% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. NVGN: -4285.14 )
Ranked among companies with meaningful Net Margin % only.
NVGN' s Net Margin % Range Over the Past 10 Years
Min: -8583.91  Med: -505.09 Max: 90.46
Current: -4285.14
-8583.91
90.46
ROE % -35.21
NVGN's ROE % is ranked lower than
83% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. NVGN: -35.21 )
Ranked among companies with meaningful ROE % only.
NVGN' s ROE % Range Over the Past 10 Years
Min: -269.02  Med: -46.41 Max: 33.98
Current: -35.21
-269.02
33.98
ROA % -27.43
NVGN's ROA % is ranked lower than
85% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. NVGN: -27.43 )
Ranked among companies with meaningful ROA % only.
NVGN' s ROA % Range Over the Past 10 Years
Min: -143.49  Med: -35.24 Max: 12.06
Current: -27.43
-143.49
12.06
ROC (Joel Greenblatt) % -622.21
NVGN's ROC (Joel Greenblatt) % is ranked lower than
90% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. NVGN: -622.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NVGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -14620.2  Med: -1886.49 Max: -622.21
Current: -622.21
-14620.2
-622.21
3-Year EBITDA Growth Rate -20.60
NVGN's 3-Year EBITDA Growth Rate is ranked higher than
89% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. NVGN: -20.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NVGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -61.1  Med: -10.45 Max: 44.2
Current: -20.6
-61.1
44.2
3-Year EPS without NRI Growth Rate -21.70
NVGN's 3-Year EPS without NRI Growth Rate is ranked higher than
78% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. NVGN: -21.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NVGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57.8  Med: -10.35 Max: 29.1
Current: -21.7
-57.8
29.1
GuruFocus has detected 4 Warning Signs with Novogen Ltd NVGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVGN's 30-Y Financials

Financials (Next Earnings Date: 2018-02-22)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

NVGN Guru Trades in Q4 2016

Jim Simons 137,300 sh (unchged)
» More
Q1 2017

NVGN Guru Trades in Q1 2017

Jim Simons 137,300 sh (unchged)
» More
Q2 2017

NVGN Guru Trades in Q2 2017

Jim Simons 137,300 sh (unchged)
» More
Q3 2017

NVGN Guru Trades in Q3 2017

Jim Simons 34,325 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NVGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic  
Compare:BOM:524764, OTCPK:PVCT, XCNQ:PUF, OTCPK:KAYS, LSE:EVG, XCNQ:TGIF, XKLS:0171, OTCPK:CYIG, BOM:537253, BUE:ROSE, ROCO:4127, NAS:SNOA, AMEX:IGC, ASX:ESE, XCNQ:TER, XCNQ:DOJA, OTCPK:PARNF, OTCPK:AOLS, BOM:524711, OTCPK:RLMD » details
Traded in other countries:NRT.Australia, NV9N.Germany, NVGNF.USA,
Headquarter Location:Australia
Novogen Ltd is a pharmaceutical drug development based on a simple benzopyran chemical structure. It is an emerging oncology-focused biotechnology company that develops anti-cancer drugs.

Novogen Ltd is engaged in pharmaceutical drug development. It develops single drug capable of killing both the dominant differentiated cells in a cancer as well as the undifferentiated cancer stem cells at a therapeutic dose. The Company's inaugural drug candidate CS-6 belongs to a new class of drug candidates known as Mitochondrial Electron Transfer Inhibitors that work by depriving the cancer cell of its main energy source. The Company's competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions. The activities of the Company are subject to numerous Australian laws and regulations.

Ratios

vs
industry
vs
history
PB Ratio 7.15
NVGN's PB Ratio is ranked higher than
96% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. NVGN: 7.15 )
Ranked among companies with meaningful PB Ratio only.
NVGN' s PB Ratio Range Over the Past 10 Years
Min: 0.08  Med: 2.75 Max: 45.56
Current: 7.15
0.08
45.56
EV-to-EBIT -0.33
NVGN's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. NVGN: -0.33 )
Ranked among companies with meaningful EV-to-EBIT only.
NVGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.9  Med: -2 Max: 1
Current: -0.33
-19.9
1
EV-to-EBITDA -0.36
NVGN's EV-to-EBITDA is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. NVGN: -0.36 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.3  Med: -2.1 Max: 1
Current: -0.36
-26.3
1
EV-to-Revenue 14.13
NVGN's EV-to-Revenue is ranked higher than
67% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. NVGN: 14.13 )
Ranked among companies with meaningful EV-to-Revenue only.
NVGN' s EV-to-Revenue Range Over the Past 10 Years
Min: -29.8  Med: 6.8 Max: 739.8
Current: 14.13
-29.8
739.8
Current Ratio 3.62
NVGN's Current Ratio is ranked higher than
91% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. NVGN: 3.62 )
Ranked among companies with meaningful Current Ratio only.
NVGN' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 6.35 Max: 25.11
Current: 3.62
0.81
25.11
Quick Ratio 3.62
NVGN's Quick Ratio is ranked higher than
92% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. NVGN: 3.62 )
Ranked among companies with meaningful Quick Ratio only.
NVGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 5.46 Max: 25.11
Current: 3.62
0.81
25.11
Days Sales Outstanding 7.33
NVGN's Days Sales Outstanding is ranked lower than
98% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. NVGN: 7.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.51  Med: 52.34 Max: 435.3
Current: 7.33
1.51
435.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -41.60
NVGN's 3-Year Average Share Buyback Ratio is ranked lower than
92% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. NVGN: -41.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -173.7  Med: -4.15 Max: 62.6
Current: -41.6
-173.7
62.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 39.13
NVGN's Price-to-Net-Cash is ranked higher than
82% of the 234 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.00 vs. NVGN: 39.13 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NVGN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.19  Med: 6.15 Max: 41.88
Current: 39.13
0.19
41.88
Price-to-Net-Current-Asset-Value 18.41
NVGN's Price-to-Net-Current-Asset-Value is ranked higher than
90% of the 474 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.23 vs. NVGN: 18.41 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NVGN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.11  Med: 4.63 Max: 19.71
Current: 18.41
0.11
19.71
Price-to-Tangible-Book 18.41
NVGN's Price-to-Tangible-Book is ranked higher than
76% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. NVGN: 18.41 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NVGN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.11  Med: 4.15 Max: 20
Current: 18.41
0.11
20
Price-to-Median-PS-Value 39.13
NVGN's Price-to-Median-PS-Value is ranked lower than
99.99% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. NVGN: 39.13 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NVGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 1.12 Max: 41.88
Current: 39.13
0.3
41.88
Earnings Yield (Greenblatt) % -307.86
NVGN's Earnings Yield (Greenblatt) % is ranked lower than
100% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. NVGN: -307.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2244.5  Med: -43.8 Max: 4977.3
Current: -307.86
-2244.5
4977.3

More Statistics

Revenue (TTM) (Mil) $0.19
EPS (TTM) $ -1.70
Beta0.95
Short Percentage of Float0.00%
52-Week Range $1.63 - 7.60
Shares Outstanding (Mil)0.48 (ADR)

Analyst Estimate

Jun18 Jun19 Jun20
Revenue (Mil $) 6 14
EPS ($) -2.76 -1.69 -0.12
EPS without NRI ($) -2.76 -1.69 -0.12
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 11
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}